Contact Us
Drug Search Results
More Filters [+]

Veledimex

Alternative Names: veledimex, inxn-1001
Latest Update: 2022-06-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CYP3A4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alaunos Therapeutics
Company Location: BOSTON MA 02129
Company CEO: Kevin S. Boyle
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Veledimex

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Scleroderma, General|Scleroderma, Systemic|Scleroderma, Diffuse|Scleroderma, Localized|Breast Cancer|Glioma|Glioblastoma|Brain Cancer

Phase 1: Astrocytoma|Glioblastoma|Glioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ATI001-103

P2

Terminated

Glioma|Brain Cancer

2021-09-10

55%
ATI001-103

P2

Terminated

Glioma|Brain Cancer

2021-09-10

55%
ATI001-204

P2

Completed

Glioblastoma

2021-08-05

57%
ATI001-204

P2

Completed

Glioblastoma

2021-08-05

57%
Protocol ATI001-102 Substudy

P1

Completed

Glioblastoma

2020-10-15

42%
Protocol ATI001-102 Substudy

P1

Completed

Glioblastoma

2020-10-15

42%
Morphea

P2

Terminated

Scleroderma, Systemic|Scleroderma, Localized|Scleroderma, General|Scleroderma, Diffuse

2020-09-23

Recent News Events

Date

Type

Title

03/10/2021

News Article

 Global Brain Cancer Market Assessment 2021-2030 - Generic Versions of Avastin (Genentech) and Temodar/Temodal (Merck), due to Patent Expiries, Creates Huge Competition

03/08/2021

News Article

 Brain Cancer 2021 - Market and Epidemiology Insights & Forecasts to 2030 - ResearchAndMarkets.com

11/19/2020

News Article

 Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting

10/29/2020

News Article

 Ziopharm Oncology to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions